Skip to main content

Company

Oxford Cannabinoid Technologies Holdings PLC

LON:OCTP

Oxford Cannabinoid Technologies Holdings PLC is a well-established, innovative and growing pharmaceutical company developing a portfolio of next generation prescription cannabinoid medicines for approval by key medicines regulatory agencies worldwide and targeting the multi-billion dollar pain market.

54 stories · page 1 of 3

British biotech joins LSE exodus

By Proactive 08/05/2024

Oxford Cannabinoid shares to be admitted for trading on February 20

By Proactive 15/02/2024

Oxford Cannabinoid Technologies files patent application for pain relief drug

By Proactive 10/01/2024

Oxford Cannabinoid appoints CMO Dr Tim Corn to the board

By Proactive 14/11/2023

Oxford Cannabinoid Technologies delighted with phase 1 outcome for pain drug

By Proactive 24/10/2023

Oxford Cannabinoid Tech stakeholder sells shares to partner

By Proactive 20/10/2023

Oxford Cannabinoid shares jump 6% on successful completion of phase I study

By Proactive 10/10/2023

Oxford Cannabinoid readies for next stage as it safely navigates phase I study

By Proactive 10/10/2023

Oxford Cannabinoid Technologies developing a portfolio of next generation prescription cannabinoid medicines

By Proactive 05/10/2023

Oxford Cannabinoid Technologies completes final dose in phase I trial of lead asset

By Proactive 25/09/2023

Oxford Cannabinoid Technologies hails defining year as clinical trials remain on track

By Proactive 31/08/2023

Oxford Cannabinoid Technologies takes pain drug into phase I; appoints leading pain expert

By Proactive 27/07/2023

Oxford Cannabinoid jumps on hints of cheaper cancer treatments

Oxford Cannabinoid formerly announced an expansion into oncology research on Monday

By Proactive 17/07/2023

Oxford Cannabinoid expands into oncology with potential new cannabinoid-based treatment

By Proactive 17/07/2023

US clamps down on cannabis edibles “nearly identical” to snacks

By Proactive 06/07/2023

Cannabis investment: budding revival as London's contenders adapt to changing market

By Proactive 28/06/2023

Oxford Cannabinoid appoints chief medical officer

By Proactive 08/06/2023

Oxford Cannabinoid rise continues as first clinical trial gets started

By Proactive 17/05/2023

Oxford Cannabinoid to start phase 1 trial for pain relief drug

By Proactive 17/05/2023

Oxford Cannabinoid Technologies shares spike on CEO appointment and licence renewal

By Proactive 12/04/2023